|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant protein containing the extreme C-terminal cytoplasmic region of the human ret oncoprotein.|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||1:10-1:20|
|Immunohistochemistry (Paraffin) (IHC (P))||1:10-1:20|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-26379 detects Ret from human samples.
MA1-26379 has been successfully used in immunohistochemistry (paraffin) procedures. Positive control: small intestine.
The MA1-26379 immunogen is recombinant protein containing the extreme C-terminal cytoplasmic region of the human ret oncoprotein.
This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed. , ,
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Key roles for MYC, KIT and RET signaling in secondary angiosarcomas.
MA1-26379 was used in immunohistochemistry to study the genetic profiles of morphologically indistinguishable primary and secondary angiosarcomas
|Styring E,Seinen J,Dominguez-Valentin M,Domanski HA,Jönsson M,von Steyern FV,Hoekstra HJ,Suurmeijer AJ,Nilbert M||British journal of cancer (111:407)||2014|
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
MA1-26379 was used in immunohistochemistry to study the biochemical activity of cabozantiinib against disease-associated RET mutants and its growth inhibitory activity in medullary thyroid cancer models
|Bentzien F,Zuzow M,Heald N,Gibson A,Shi Y,Goon L,Yu P,Engst S,Zhang W,Huang D,Zhao L,Vysotskaia V,Chu F,Bautista R,Cancilla B,Lamb P,Joly AH,Yakes FM||Thyroid : official journal of the American Thyroid Association (23:1569)||2013|
Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma.
MA1-26379 was used in immunohistochemistry to study the immunoreactivity of Ret in adrenal medullary hyperplasia and pheochromocytomas
|Powers JF,Brachold JM,Tischler AS||Endocrine pathology (14:351)||2004|
New insights into c-Ret signalling pathway in the enteric nervous system and its relationship with ALS.
MA1-26379 was used in immunocytochemistry and immunohistochemistry to study the neuronal expression and localization of c-Ret within the adult human enteric nervous system and the implications for ALS
|Luesma MJ,Cantarero I,Álvarez-Dotu JM,Santander S,Junquera C||BioMed research international (2014:null)||2014|